Natixis Aeterna Zentaris Inc. Transaction History

Natixis

  • $17.6 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$0.36 - $0.77 $105,768 - $226,226
-293,800 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$0.59 - $0.88 $41,713 - $62,216
70,700 Added 31.69%
293,800 $220,000
Q2 2021

Aug 13, 2021
BUY
$0.83 - $1.14 $185,173 - $254,333
223,100 New
223,100 $196,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email